Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. - Wikidata - awgldk - TriplyDB

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

http://www.wikidata.org/entity/Q33421108

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Emerging treatment options for myelofibrosis: focus on pacritinib Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Clinical potential of pacritinib in the treatment of myelofibrosis Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Emerging drugs for the treatment of myelofibrosis.Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.A comprehensive review of pacritinib in myelofibrosis.Pacritinib: a new agent for the management of myelofibrosis?Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.Myeloproliferative neoplasms: A decade of discoveries and treatment advances.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Primary myelofibrosis and its targeted therapy.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Myelofibrosis: an update on drug therapy in 2016.Treatment of Myelofibrosis: Old and New Strategies.Epigenetics in Myeloproliferative Neoplasms.Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.Myeloproliferative neoplasms and personalized medicine: the perfect match?The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.Developmental Therapeutics in Myeloproliferative Neoplasms.Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

P2860

Q26738514-7AA00022-D63A-4620-BC4D-F4F36B1651EC Q26745939-E6530631-6C97-4D85-BAC5-879CBC790135 Q26752940-B0CD4CDE-2A75-4273-875D-1BEB4103798A Q26766319-2322FBB7-D183-449D-8DF4-3E117FD54282 Q26796450-518C1ACD-03F4-4B28-A545-893F9997D115 Q28073296-94F224BD-DAB8-4622-B83F-E23E7D2B4951 Q30244032-462BFE4F-678E-4834-8954-BEA3B27E3662 Q33429873-59C43989-5A95-43B6-8CA9-C65D9CCD0D9C Q33430113-A69C89B7-0B2C-4270-9C47-4C125A45E8E1 Q33432285-2BCC26E5-575F-4D28-8047-1D2BFCE205E6 Q33432406-570C9982-7F9D-494E-B731-B1D4AF0E1CFC Q33435178-63B6571C-220F-4415-9509-3FECF5B1418E Q33435398-644C1A44-ACC9-4167-BB45-D40B683F1ADE Q33437478-8C6BCE6C-5C95-49A7-B933-5E8B1D91465F Q36782943-20835EC4-5440-4A11-89FE-2AD470A64DD2 Q38543775-BA349F02-25D1-4B00-8792-E73411AF6706 Q38567540-4B6549C2-5B78-4A33-9816-895AF62ADC3F Q38586421-E09C28A8-16A1-46BC-BB6F-6FE1620BF19F Q38590232-B5F9CA4A-A08F-4B0A-AF67-139928657FB9 Q38594107-D16300A1-B3A3-4265-A5FC-42464E6B5523 Q38613880-11B8093A-6680-48B0-A661-75BC9FE6DA03 Q38684435-15A363CC-ECA2-49DA-8951-331FF7A6ED8D Q38691019-2504CC1F-3AAB-437E-8DF5-30CC63687989 Q38924189-D7AFC469-6A72-4427-A9A2-BDBE8413C476 Q38931426-5470675F-0C61-4C38-9697-294DB37E5EB5 Q38984578-4B5BE026-04E0-4157-89EB-BD09A727034E Q38989215-D1CCDAC5-9439-4587-81C2-9E4D1D3898AB Q39349869-021D51B0-99CE-4F20-A8E1-70C48CBD8252 Q39414554-5D2E86F5-D51E-4D6E-AAAD-39CF9ECA6C2B Q39869997-9CFA5893-BBE6-4E7B-BAE3-C28F5766156C Q41160178-8C727C68-D77C-4C88-B34D-50D1C5554F17 Q43146989-D439A9C4-2C8F-46D7-96C5-F3D98451A776 Q47134413-00666FC5-44FC-4E68-862E-7338F3532A7E Q47581193-2F6A43D6-160D-47A0-AA4F-C62F3B7FA005 Q47784419-560923BB-4D89-4247-83A8-B0EC5B088B6E Q48008083-CE2E40F8-2F46-4670-93B3-9DFE069F23A3 Q50042813-42EE0BDE-78F1-461D-A91B-EA5372C85839 Q50191433-77C0CAE7-884E-4EC6-B097-854AFF23EBBB Q51737052-01D8DD22-29EB-4B78-88BD-59F7FD1DA705 Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856

P2860

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

http://www.wikidata.org/entity/Q33421108

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Results of a phase 2 study of ...... n patients with myelofibrosis.

@ast

Results of a phase 2 study of ...... n patients with myelofibrosis.

@en

type

label

Results of a phase 2 study of ...... n patients with myelofibrosis.

@ast

Results of a phase 2 study of ...... n patients with myelofibrosis.

@en

prefLabel

Results of a phase 2 study of ...... n patients with myelofibrosis.

@ast

Results of a phase 2 study of ...... n patients with myelofibrosis.

@en

P1433

Q33421108-34313B8A-5368-4415-A887-F26182D5B8AA

P1476

Q33421108-F24C4C8F-B0F9-4B92-BB75-EABAF55C4EA5

P2093

Q33421108-081FF998-95AF-419A-9E28-37A836C55D72

Q33421108-1319EC9B-F5B3-4998-A8ED-66944B666687

Q33421108-1F227F58-8BEA-463A-9085-C6A1FFE965E4

Q33421108-5214A142-1877-41DD-AED6-17CB742AFC96

Q33421108-7805337E-BA33-4642-97DA-DCE5961D4650

Q33421108-9F889485-DF0B-4B71-8369-79246A5C46FF

Q33421108-A85EE745-46B8-4F25-88D5-C9D22249E67F

Q33421108-B15E5F8E-DE93-4A92-93F6-D9161EE1BB76

Q33421108-B34B1F0F-6446-42E0-AB4D-D3F9F23A8273

Q33421108-BE99CDA9-CF7E-4DA7-A7C0-7C245003DB1B

P2860

Q33421108-0F3B79A7-F261-4639-95E1-9B56795A3E23

Q33421108-148048C9-401B-4015-B55D-331BE5B2A33D

Q33421108-1ABD8A3B-3D77-4D6B-A1BA-F3D8A65CB52F

Q33421108-34982411-67C3-4BD6-BDAB-53DA34ED0B1F

Q33421108-40F2732A-495D-471E-80DC-F800579353DB

Q33421108-45B52B95-E300-408D-B0D5-E16CD48BAD70

Q33421108-4EF4A97E-2149-415F-A0FC-67AC6E77A0CF

Q33421108-5505F76B-4B22-43C8-BDED-740FD00FEDD4

Q33421108-5A270244-20EC-4618-8FA9-A721966EF9F7

Q33421108-6BEC3CB3-3955-4FA5-A5F2-C2FA9261E6B8

P304

Q33421108-5EA80669-358B-4CA1-80B4-564884DA26F3

P31

Q33421108-22ADD948-2B9B-4AF2-8C39-DCEB32A8E73D

P356

Q33421108-28E60F42-8B60-4F21-A088-7B6A37FDE3F5

P407

Q33421108-74DDEE91-92D9-4F6E-A8CD-7E3A79AC6A29

P433

Q33421108-1571CB58-BAAA-4ADF-9151-0884A79F0861

P478

Q33421108-738F9671-CBC6-45DB-A9DC-D3E21CDB0AA8

P50

Q33421108-3C18F036-979F-4360-9684-0F8C35D1B8C7

Q33421108-91816F94-75B4-4BAA-9CB7-7112798BF988

P577

Q33421108-7E0502A4-9AB5-49FA-AE87-F43A85B26AB9

P5875

Q33421108-74475AE1-0A1F-44ED-A497-4439228DD033

P698

Q33421108-1250A228-2030-4D89-90E9-5684FFB9D402

P932

Q33421108-5DFA137F-CE3C-4BA3-A2BC-D9ADAED746FC

P356

BLOOD-2013-02-484832

P1433

P1476

Results of a phase 2 study of ...... n patients with myelofibrosis.

@en

P2093

Andrew Dorr

http://www.w3.org/2001/XMLSchema#string

Elyce Turba

http://www.w3.org/2001/XMLSchema#string

John F Seymour

http://www.w3.org/2001/XMLSchema#string

Joy Zhu

http://www.w3.org/2001/XMLSchema#string

L Bik To

http://www.w3.org/2001/XMLSchema#string

Lixia Wang

http://www.w3.org/2001/XMLSchema#string

Mary S Campbell

http://www.w3.org/2001/XMLSchema#string

Rami S Komrokji

http://www.w3.org/2001/XMLSchema#string

Robyn Scherber

http://www.w3.org/2001/XMLSchema#string

Ruben A Mesa

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the management of myelofibrosis

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Somatic mutations of calreticulin in myeloproliferative neoplasms.

P304

2649-2655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-02-484832

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Martha Wadleigh

Andrew W Roberts

P577

2015-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273786662

http://www.w3.org/2001/XMLSchema#string

P698

25762180

http://www.w3.org/2001/XMLSchema#string

P932

4490373

http://www.w3.org/2001/XMLSchema#string